| News
Hemex banks 7.1 million Swiss francs
29.11.2021
Hemex has raised a total of 7.1 million Swiss francs as part of a Series C financing round. The company for clinical contract research and investments in startups intends to finance firms in their early phase in addition to supporting plans aimed at hiring new team members.

Hemex has successfully closed a second tranche of its Series C financing round, further details of which can be found in a press release. In so doing, the company for clinical contract research and investments in startups active in the healthcare industry has so far raised a total of 7.1 million Swiss francs in the year to date.
Hemex, a partner of the investment and innovation promotion agency Basel Area Business & Innovation, intends to use this fresh capital injection to finance initial investments in early-phase startups active in the field of life sciences. Moreover, the company, which is based in Liestal in the canton of Basel-Landschaft, will seek to recruit new team members for clinical activities, quality assurance and regulatory matters.
The support from both existing and new investors “shows the potential of our business model”, comments co-founder and CEO Pascal Winnen in the press release. “With our fast-growing team of highly qualified healthcare professionals as well as a strong network of specialized consultants, we will continue to offer our shareholders the opportunity to identify and invest in early-stage healthcare startups, with active management of the portfolio”, he adds.
Share this article
Sign up to receive our newsletter in your inbox.
You may also be interested in
Evolva launches new line for manufacturers of personal care products
Evolva, a manufacturer of active ingredients based in Reinach in the canton of Basel-Landschaft, will be presenting its new product...
Read MoreRecord figure for startups in the Basel Area
Basel Area Business & Innovation has supported a record number of 96 company startups in 2022. The number of settlements...
Read MoreNoema Pharma raises 103 million Swiss francs from investors
Noema Pharma has raised a total of 103 million Swiss francs as part of an oversubscribed Series B financing round....
Read MoreWhy CDMO companies choose the Basel Area as their location
Originally, this article was published by the US magazine Outsourced Pharma under the title "Why Location Matters". The article highlights...
Read MoreBasel still the most attractive small city for business in Europe
As with last year, Basel once again features among the most attractive locations in Europe for investments. It was ranked...
Read MoreAriceum Therapeutics establishes subsidiary in Basel
The German life sciences firm Ariceum Therapeutics has established a subsidiary in Basel. This company has received support from Basel...
Read More